How can conformance with GMP requirements for active substances be proven?

17.04.2023

Question of the Week

European medicinal product manufacturers are obliged to use as starting materials only active substances that have been manufactured in compliance with EU GMP requirements. This proof is provided by EU GMP certificates, GMP certificates from authorities in third countries with a mutual recognition agreement (MRA and ACAA) and written confirmations from authorities in third countries.

[GMP Compliance Adviser, Chapter 20.D]

Would you like to discover more?

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

24.11.2025

Question of the Week

How is a QRM process initiated?

You can view the answer here:

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.